iLoF combines artificial intelligence with photonics to speed up personalized drug discovery by turning light signals from small, non-invasive blood samples into optical fingerprints stored in a cloud library. The platform collects light signals, creates fingerprints, uploads them to the cloud, and uses AI to extract data and identify biomarkers to guide patient stratification for trials. It differentiates itself by linking non-invasive optical fingerprints with a cloud-based data library and offering a data-access subscription and end-to-end service for pharma, enabling scalable biomarker discovery and patient grouping. Its goal is to shorten drug development timelines and trial screening costs by providing AI-driven, non-invasive biomarker insights for more patient-centric studies.
Company Size
11-50
Company Stage
Early VC
Total Funding
$13M
Headquarters
London, United Kingdom
Founded
2019
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?